论文部分内容阅读
自20世纪70年代起,亚洲的乳腺癌发病率呈上升趋势[1]。化疗作为预防乳腺癌复发和转移的有效手段已获得公认。对于存在复发和转移高危风险的患者而言,剂量密集AC(多柔比星+环磷酰胺)序贯紫杉醇是一种较好的化疗方案,可以提高这类患者的疗效和耐受性。本科于2009年1月—2010年12月应用小牛脾提取物注射液联合剂量密集AC4个周期序贯紫杉醇4个周期方案用于乳腺癌术后患者的化疗,观察其不良反应,现将结果报道如下。
Since the 1970s, the incidence of breast cancer in Asia has been on the rise [1]. Chemotherapy has proven to be an effective means of preventing the recurrence and metastasis of breast cancer. Dose-intensive AC (doxorubicin + cyclophosphamide) sequential paclitaxel is a good chemotherapy regimen for patients with a high risk of recurrence and metastases, and may improve the efficacy and tolerability of these patients. Undergraduate in January 2009 - December 2010 application of calf spleen extract injection combined with dose-intensive AC4 cycles of sequential paclitaxel 4 cycles of chemotherapy for patients with postoperative breast cancer and observe the adverse reactions, the results will now Reported as follows.